Key result
African Americans show no difference in avoidable CHF hospitalizations despite receiving fewer beta blockers and ACEi/ARBs.
Why the study?
Equitable access to health insurance coverage may improve outcomes and mitigate racial/ethnic disparities in congestive heart failure treatment and outcomes among TRICARE beneficiaries.
Does race/ethnicity affect the receipt of pharmacological therapy and the likelihood of potentially avoidable hospitalizations in TRICARE beneficiaries with congestive heart failure?
Population
2183 TRICARE beneficiaries with CHF representing 115,584 after survey weighting
Comparison
African American and Hispanic vs White race/ethnicity
Design
Retrospective cohort analysis
Authors
Loading...
Medication disparities did not increase avoidable HF hospitalizations in TRICARE; leaves open generalizability and causality in other systems.
Cohort (n=2,183)
Does race/ethnicity affect the receipt of pharmacological therapy and the likelihood of potentially avoidable hospitalizations in TRICARE beneficiaries with congestive heart failure?
In an equal-access healthcare system (TRICARE), racial disparities in the prescription of heart failure medications exist but do not result in disparities in potentially avoidable hospitalizations.
Bagchi et al. (2011) conducted a cohort in Congestive heart failure (CHF) (n=2,183). Race/Ethnicity (African American and Hispanic) vs. White race was evaluated on Any CHF-related potentially avoidable hospitalizations (PAHs). Although African American beneficiaries were less likely than whites to receive beta blockers and ACE inhibitors/ARBs (P<0.0001), there were no significant racial/ethnic differences in the odds of a potentially avoidable hospitalization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: